or the tempus fugit frisson you get when you open and read a crumpled ball of newspaper once used to wrap a rediscovered vase in the attic — have no equivalents in other media modalities.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

CHICAGO, May 14, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Gifting allows recipients to access the article for free. Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological ...

Tempus AI TEM underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings ...

Weather drawing by Daphne of Mrs. Maurer's third grade class at Baxter Elementary School. Attention teachers: Don't forget to submit your students' weather drawing to the Brainerd Dispatch ...